Evidence map›Paper›PMID 38340697›Full record

ArticleJournal of psychiatric research2024

Cerebrospinal fluid proteomic signatures are associated with symptom severity of first-episode psychosis.

Humza Haroon, Ada Man-Choi Ho, Vinod K Gupta, Surendra Dasari, Carl M Sellgren, Simon Cervenka, Göran Engberg, Feride Eren, Sophie Erhardt, Jaeyun Sung and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatric research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Humza HaroonDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Ada Man-Choi HoDepartment of Psychiatry and Psychology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Vinod K GuptaDivision of Surgery Research, Department of Surgery, Rochester, MN, USA; Microbiome Program, Center for Individualized Medicine, Rochester, MN, USA.
Surendra DasariDivision of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Carl M SellgrenDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
Simon CervenkaCentre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden; Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.
Göran EngbergDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Feride ErenDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Sophie ErhardtDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Jaeyun SungDivision of Surgery Research, Department of Surgery, Rochester, MN, USA; Microbiome Program, Center for Individualized Medicine, Rochester, MN, USA; Division of Rheumatology, Department of Internal Medicine, Rochester, MN, USA.
Doo-Sup ChoiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Department of Psychiatry and Psychology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Neuroscience Program, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. Electronic address: choids@mayo.edu.
Mayo Clinic · USKarolinska Institutet · SEUppsala University · SE

Funding

Chronic Alcohol Exposure and Pathophysiology of Alzheimer's Disease.R01AG072898 · NIA · MAYO CLINIC ROCHESTER · PI CHOI, DOO-SUP, TRUSHINA, EUGENIA · 2020 to 2024
$2.0M
Astrocyte-Neuron Interaction in the Dorsal Striatum and Ethanol-Seeking Behaviors Diversity supplement - Matthew LopezR01AA029258 · NIAAA · MAYO CLINIC ROCHESTER · PI CHOI, DOO-SUP · 2021 to 2025
$1.8M
Neural Basis of Ethanol Withdrawal-Induced Sleep DisturbanceR21AA028968 · NIAAA · MAYO CLINIC ROCHESTER · PI CHOI, DOO-SUP · 2021 to 2022
$417k
NIAAA NIH HHS R01 AA029258NIAAA NIH HHS R21 AA028968NIA NIH HHS R01 AG072898
6 · The paper itself

Abstract

Apart from their diagnostic, monitoring, or prognostic utility in clinical settings, molecular biomarkers may be instrumental in understanding the pathophysiology of psychiatric disorders, including schizophrenia. Using untargeted metabolomics, we recently identified eight cerebrospinal fluid (CSF) metabolites unique to first-episode psychosis (FEP) subjects compared to healthy controls (HC). In this study, we sought to investigate the CSF proteomic signatures associated with FEP. We employed 16-plex tandem mass tag (TMT) mass spectrometry (MS) to examine the relative protein abundance in CSF samples of 15 individuals diagnosed with FEP and 15 age-and-sex-matched healthy controls (HC). Multiple linear regression model (MLRM) identified 16 differentially abundant CSF proteins between FEP and HC at p < 0.01. Among them, the two most significant CSF proteins were collagen alpha-2 (IV) chain (COL4A2: standard mean difference [SMD] = -1.12, p = 1.64 × 10

Indexed as

Psychotic DisordersSchizophreniaHumansProteomicsCerebrospinal fluidFirst-episode psychosisProteomicsSchizophrenia

Identifiers

PMID38340697
PMCPMC10995989
OpenAlexW4391471424

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.